* Angiogenesis Technologies Inc., of Vancouver, Canada, haslicensed from Mount Sinai Hospital Corp., of Toronto, technologyfor developing treatments aimed at proliferative disorders, metastasesand drug resistant tumors using vanadate, a salt derived fromvanadium. The technology involves using vanadate to inhibittranscription factors implicated in the proliferation of malignant cells.
* Apex Bioscience Inc., of Research Triangle Park, N.C., began aPhase I safety trial of piridoxilate hemoglobin polyoxethylene (PHP)in the U.S. The drug is being developed as a treatment for acutenitric-oxide mediated hypotension and as an adjunct to cancerchemotherapy.
* Celgene Corp., of Warren, N.J., began trials of Synovir, orthalidomide, for rheumatoid arthritis at New York UniversityHospital of Joint Diseases. The company said thalidomide is aninhibitor of tumor necrosis factor alpha, which has been linked to thedisease.
* Chemtrak Inc., of Sunnyvale, Calif., said the FDA cleared itsAccumeter high density lipoprotein test for use by health careprofessionals to detect good and bad cholesterol. The company said itintends to file for approval of the test for use by consumers this year.
* Cortecs International Ltd., of London, entered an agreement withDenmark-based Osteometer BioTech A/S for development of a test todetect collagen breakdown, which is an indicator of osteoporosis.
* Gensia Inc., of San Diego, and Atrix Laboratories Inc., of FortCollins, Colo., have agreed to co-develop a treatment of solid tumorcancers based on Atrix's Atrigel drug delivery system. The productwill combine an existing anti-cancer drug with the Atrigel controlled-release technology, eliminating the need for daily injections.
* ImmuLogic Pharmaceutical Corp., of Waltham, Mass., said it hasclosed its Palo Alto, Calif. facility and is consolidating researchoperations in Waltham. The company said it expects to save $5million a year by shutting down the Palo Alto plant and bystreamlining other operations.
* Quadra Logic Technologies Inc., of Vancouver, Canada, and itspartner, Ciba Vision Ophthalmics, a subsidiary of Switzerland-basedCiba-Geigy Ltd., began a Phase I study of benzoporphyrin derivative,a light-activated drug, for treatment of age-related maculardegeneration.
* Quintiles Transnational Corp., of Morrisville, N.C., acquired twocontract research organizations recently. The company boughtFrance-based Benefit International S.A. and its subsidiaries for $16million in cash and stock and purchased San Diego Clinical *Research Associates in a stock swap valued at $3.4 million.
* Synsorb Biotech Inc., of Calgary, Canada, has proposed theacquisition of Chembiomed Ltd., of Edmonton, Canada. Synsorb saidit was founded with technology developed by Chembiomed.
* Hemosol Inc., of Toronto, said Phase I studies of Hemolink, its firsthuman red blood cell substitute, were started in Montreal.
* ID Biomedical Corp., of Vancouver, B.C., closed on a previouslyannounced private placement of 445,000 special warrants atCanadian $18 apiece, for gross proceeds of about Canadian $8million.
* Pharmacia Biotech AB, of New York, introduced ALFexpress, anautomated DNA sequencer for sequencing and fragment analysis.
* Sheffield Medical Technologies Inc., of New York, closed a privateplacement of 412,500 units, at $8 apiece, and received $3.3. Eachunit consisted of two shares of the company's stock (AMEX:SHM)and a warrant to purchase one share at $5.
(c) 1997 American Health Consultants. All rights reserved.